Since metformin inhibits the mTOR/p3K pathway [6], it seems attractive to test this drug in tumours which harbour mTOR hyperactivation, such as neuroendocrine tumours (to be initiated by our group) and breast cancer (NCT01101438) [20]. The gene discussed is MTOR; the disease is neuroendocrine neoplasm.